Graft-versus-host disease medical therapy: Difference between revisions
Gerald Chi- (talk | contribs) |
m (Categories) |
||
| Line 11: | Line 11: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | |||
{{WH}} | |||
[[Category:Primary care]] | [[Category:Primary care]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category: | [[Category:Immunology]] | ||
Revision as of 16:08, 17 June 2016
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease medical therapy On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease medical therapy |
|
Risk calculators and risk factors for Graft-versus-host disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Intravenously administered corticosteroids, such as prednisone, are the standard of care in acute GVHD[1] and chronic GVHD. The use of these corticosteroids is designed to suppress the T-cell mediated immune onslaught on the host tissues; however in high doses this immune-suppression raises the risk of infections and cancer relapse. Therefore it is desirable to taper off the post-transplant high level steroid doses to lower levels, at which point the appearance of mild GVHD may be welcome, especially in HLA mis-matched patients, as it is typically associated with a graft-versus-tumor effect.
References
- ↑ Goker H, Haznedaroglu IC, Chao NJ (2001). "Acute graft-vs-host disease: pathobiology and management". Exp. Hematol. 29 (3): 259–77. PMID 11274753.